Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study

Journal of Microencapsulation

Volumn 32, Issue 6, 2015, Pages 589-597

  Mooranian, Armin ^a   Negrulj, Rebecca ^a   Mikov, Momir ^b,c   Golocorbin Kon, Svetlana ^b,c   Arfuso, Frank ^a   Al Salami, Hani ^a  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF NOVI SAD   (Serbia)

^c UNIVERSITY OF MONTENEGRO   (Montenegro)

Author keywords

Bile acids; Chenodeoxycholic acid; Microencapsulation; Probucol; Type 2 diabetes mellitus

Indexed keywords

ALGINIC ACID; CHENODEOXYCHOLIC ACID; PROBUCOL; BILE ACID; GLUCURONIC ACID; HEXURONIC ACID; MICROCAPSULE; POWDER;

ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; ENERGY DISPERSIVE X RAY SPECTROSCOPY; EVIDENCE BASED PRACTICE; EXCIPIENT COMPATIBILITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MICRO-COMPUTED TOMOGRAPHY; MICROCAPSULE; MICROENCAPSULATION; PARTICLE SIZE; PH; PHARMACOPHORE; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SPECTROSCOPY; SURFACE PROPERTY; THERMAL ANALYSIS; ZETA POTENTIAL; CHEMISTRY; DIABETES MELLITUS, TYPE 2; FLOW KINETICS; HUMAN; ORAL DRUG ADMINISTRATION; POWDER; TEMPERATURE; VISCOSITY;

ADMINISTRATION, ORAL; ALGINATES; BILE ACIDS AND SALTS; CALORIMETRY, DIFFERENTIAL SCANNING; CAPSULES; CHENODEOXYCHOLIC ACID; DIABETES MELLITUS, TYPE 2; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POWDERS; PROBUCOL; RHEOLOGY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; TEMPERATURE; VISCOSITY; X-RAY MICROTOMOGRAPHY;

EID: 84940906595     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2015.1065922     Document Type: Article

References (41)

1. Ajun W, Yan S, Li G, Huili L. Preparation of aspirin and probucol in combination loaded chitosan nanoparticles and in vitro release study. Carbohydr Polym, 2009; 75: 566-74
2. Awasthi R, Kulkarni GT. Development of novel gastroretentive floating particulate drug delivery system of gliclazide. Curr Drug Deliv, 2012; 9: 437-51
3. Awasthi R, Kulkarni GT. Development of novel gastroretentive drug delivery system of gliclazide: Hollow beads. Drug Dev Ind Pharm, 2014; 40: 398-408
4. Barnett R. Historical keyword: Diabetes. Lancet, 2010; 375: 191
5. Bonino CA, Samorezov JE, Jeon O, Alsberg E, Khan SA. Real-time in situ rheology of alginate hydrogel photocrosslinking. Soft Matter, 2011; 7: 11510-17
6. Buckley MM, Goa KL, Price AH, Brogden RN. Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs, 1989; 37: 761-800
7. Chittleborough CR, Grant JF, Phillips PJ, Taylor AW. The increasing prevalence of diabetes in South Australia: The relationship with population ageing and obesity. Public Health, 2007; 121: 92-9
8. Davignon J. 1990. Probucol revisited. In: Descovich G, Gaddi A, Magri G, Lenzi S., eds. Atherosclerosis and cardiovascular disease. Netherlands: Springer, pp. 449-59
9. Davignon J. 1994. Probucol, principles and treatment of lipoprotein disorders. Berlin, Heidelberg: Springer, 429 - 69
10. de Celis Alonso B, Rayment P, Ciampi E, Ablett S, Marciani L, Spiller RC, Norton IT, Gowland PA. NMR relaxometry and rheology of ionic and acid alginate gels. Carbohydr Polym, 2010; 82: 663-9
11. Draget KI, Taylor C. Chemical, physical and biological properties of alginates and their biomedical implications. Food Hydrocolloids, 2011; 25: 251-6
12. George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: Alginate and chitosan-A review. J Control Release: Official Journal of the Controlled Release Society, 2006; 114: 1-14
13. Gill P, Moghadam TT, Ranjbar B. Differential scanning calorimetry techniques: Applications in biology and nanoscience. J Biomol Tech, 2010; 21: 167-93
14. Gorogawa S, Kajimoto Y, Umayahara Y, Kaneto H, Watada H, Kuroda A, Kawamori D, Yasuda T, Matsuhisa M, Yamasaki Y, Hori M. Probucol preserves pancreatic beta-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res Clin Pract, 2002; 7: 1-10
15. Heel RC, Brogden RN, Speight TM, Avery GS. Probucol: A review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia. Drugs, 1978; 15: 409-28
16. Kandrac J, Kevresan S, Gu JK, Mikov M, Fawcett JP, Kuhajda K. Isolation and determination of bile acids. Eur J Drug Metab Pharmacokinetics, 2006; 1: 157-77
17. Kuhajda K, Kandrac J, Kevresan S, Mikov M, Fawcett JP. Structure and origin of bile acids: An overview. Eur J Drug Metab Pharmacokinetics, 2006; 31: 135-43
18. Kulkarni AR, Soppimath KS, Aminabhavi TM, Rudzinski WE. In-vitro release kinetics of cefadroxil-loaded sodium alginate interpenetrating network beads. Eur J Pharm Biopharm, 2001; 51: 127-33
19. Legrand J, Dumont E, Comiti J, Fayolle F. Diffusion coefficients of ferricyanide ions in polymeric solutions-Comparison of different experimental methods. Electrochim Acta, 2000; 45: 1791-803
20. Mooranian A, Negrulj R, Al-Sallami HS, Fang Z, Mikov M, Golocorbin-Kon S, Fakhoury M, Watts GF, Matthews V, Arfuso F, et al. Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes. AAPS PharmSciTech, 2015; 16: 45 - 52
21. Mooranian A, Negrulj R, Arfuso F, Al-Salami H. Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells. Artif Cells Nanomed Biotechnol, 2014a. [Epub ahead of print]. doi: 10.3109/21691401.2014.934457
22. Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur T, Mikov M, Golocorbin-Kon S, Fakhoury M, Arfuso F. Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A characterization study. Drug Design Dev Ther, 2014b; 8: 1003
23. Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur T, Mikov M, Golocorbin-Kon S, Fakhoury M, Watts GF, et al. Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Design Dev Ther, 2014c; 8: 1221-30
24. Mooranian A, Negrulj R, Chen-Tan N, Watts GF, Arfuso F, Al-Salami H. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Design Dev Therm, 2014d; 8: 1673-83
25. Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, Mukkur T, Mikov M, Lalic-Popovic M, Stojančević M. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: The use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innov, 2014e; 9: 150-7
26. Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, Mukkur TK, Mikov M, Lalic-Popovic M, Stojancevic M, et al. An advanced microencapsulated system: A platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol, 2014f. [Epub ahead of print]. doi: 10.3109/10837450.2014.915570
27. Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, Mukkur TK, Mikov M, Lalic-Popovic M, Stojancevic M, et al. An advanced microencapsulated system: A platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol, 2014g. [Epub ahead of print]. doi: 10.3109/10837450.2014.915570
28. Negrulj R, Mooranian A, Al-Salami H. Potentials and limitations of bile acids in type 2 diabetes mellitus: Applications of microencapsulation as a novel oral delivery system. J Endocrinol Diabetes Mellitus, 2013; 1: 49-59
29. Pamies R, Schmidt RR, Martínez MdCL, Torre JGdl. The influence of mono and divalent cations on dilute and non-dilute aqueous solutions of sodium alginates. Carbohydr Polym, 2010; 80: 248-53
30. Schmid KL, Schmid LM, Pedersen C. Knowledge of the ocular effects of diabetes among the general population of Australia and the members of Diabetes Australia. Clin Exp Optom, 2003; 86: 91-103
31. Schulze MB, Shai I, Manson JE, Li T, Rifai N, Jiang R, Hu FB. Joint role of non-HDL cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes. Diabetologia, 2004; 47: 2129-36
32. Shimizu H, Uehara Y, Shimomura Y, Tanaka Y, Kobayashi I. Probucol attenuated hyperglycemia in multiple low-dose streptozotocin-induced diabetic mice. Life Sci, 1991; 49: 1331-8
33. Suzuki H, Ogawa M, Hironaka K, Ito K, Sunada H. A nifedipine coground mixture with sodium deoxycholate. I. Colloidal particle formation and solid-state analysis. Drug Dev Ind Pharmacy, 2001; 27: 943-9
34. Takka S, Cali AG. Bile salt-reinforced alginate-chitosan beads. Pharm Dev Technol, 2012; 17: 23-9
35. Tanaka Y, Inkyo M, Yumoto R, Nagai J, Takano M, Nagata S. Nanoparticulation of probucol, a poorly water-soluble drug, using a novel wet-milling process to improve in vitro dissolution and in vivo oral absorption. Drug Dev Ind Pharmacy, 2012; 38: 1015-23
36. Tanous D, Hime N, Stocker R. Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds. Redox Rep: Commun Free Radical Res, 2008; 13: 48-59
37. Torpy JM, Lynm C, Glass RM. DIabetes. JAMA, 2009; 301: 1620
38. Whelehan M, Marison IW. Microencapsulation using vibrating technology. J Microencapsul, 2011; 28: 669-88
39. Yamamoto K, Fukuda N, Shiroi S, Shiotsuki Y, Nagata Y, Tani T, Sakai T. Effects of dietary fat levels on the absorption and tissue accumulation of probucol in the rat. Arzneimittel-Forschung, 1994; 44: 1059-62
40. Yamashita S, Matsuzawa Y. Where are we with probucol: A new life for an old drug? Atherosclerosis, 2009; 207: 16-23
41. Yang Y, Campanella OH, Hamaker BR, Zhang G, Gu Z. Rheological investigation of alginate chain interactions induced by concentrating calcium cations. Food Hydrocolloids, 2013; 30: 26-32